Background. Mass drug administration (MDA), with or without low-dose primaquine (PMQ LD ), is being considered for malaria elimination programs. The potential of PMQ LD to block malaria transmission by mosquitoes must be balanced against liabilities of its use.
Malaria infects ~210 million people and kills nearly 0.5 million people annually, with ~90% of malaria deaths in Africa [1] . In the Union of Comoros, Plasmodium falciparum infections have historically accounted for 15-30% of hospitalizations and 15-20% of registered deaths in the pediatric services [2] . To eliminate this burden, the Comoros National Health Development Plan for 2010-2014 aimed to reduce parasite carriage rates to <5% [3] . Objectives included access for all Comorians to long-lasting insecticide-treated nets, indoor residual spraying, intermittent presumptive treatment for pregnant women, medical care for malaria, and implementations of mass drug administration (MDA).
An important goal of MDA is the comprehensive treatment of asymptomatic parasite carriers who silently sustain transmission in endemic populations [4, 5] . MDA regimens have therefore included primaquine (PMQ) to kill the P. falciparum gametocytes that infect mosquitoes. A single dose of PMQ (0.25 mg base/ kg) may clear P. falciparum gametocytes without serious complications from G6PD deficiency [6] . In a modeling study, low-dose PMQ (PMQ LD ; 9 mg adult dose) was predicted to enhance the transmission blocking effect of MDA with artemisinin-based combination therapy (ACT) [7] . Indeed, MDA of artemisinin-piperaquine (AP; Artequick) plus PMQ LD (AP + PMQ LD ) rapidly and dramatically reduced the parasite carriage rates in 3653 individuals in 17 villages of Kampong Speu Province, Cambodia [8] .
MDA regimens of ACT, with or without PMQ LD , are under evaluation for use in malaria elimination programs [9] . The potential of these regimens spurs interest in questions that include: (1) where and when is MDA application most effective and sustainable, (2) in what settings can inclusion of PMQ LD as a gametocidal drug improve MDA outcomes, (3) how do the benefits of the individual drugs balance against the liabilities of their use and attendant possibilities of adverse events, including the risks and contraindications of primaquine in conditions of G6PD-deficiency and early pregnancy, and (4) what are the possibilities of inducing drug resistance? Here we report on MDA of AP with or without PMQ LD in 2 cohorts totaling 85-93% of the ~322 000 inhabitants of Anjouan Island, Union of Comoros. We compare MDA outcomes with malariometrics in a population of ~420 000 on Grande Comore Island, where control programs of bednet distributions, diagnosis, and treatment continued without MDA. Finally, we survey the occurrences of mutations in the PfK13 Kelch-propeller sequence, which has been associated with a P. falciparum ring-stage artemisinin survival phenotype in Southeast Asia [10] .
METHODS

Study Areas
Anjouan Island (Ndzuwani) includes an area of 424 km 2 with 321 635 inhabitants residing in 97 villages of 7 districts (Supplementary Figure 1) ; nearby Grande Comore Island (Ngazidja) has an area of 1147 km 2 with ~420 000 inhabitants (2012 estimates). Malaria on Anjouan is transmitted principally by Anopheles gambiae and Anopheles funestus, with strong regional and seasonal variations, whereas transmission on Grande Comore is by An. gambiae and largely hyperendemic [11, 12] . Nearly all reported malaria cases are from P. falciparum infections [13] .
Community Permission, Informed Consent, Engagement and Information Distribution
The protocol and informed consent forms for this study were approved by the Ethics Committees of Comoros Ministry of Health (No. 12521/MSSPG/CAB) and Guangzhou University of Chinese Medicine (No. 2012L0816). MDA programs were established with the approval of village leaders and religious elders under community permission [14] , in collaboration with representatives of the National Malaria Control Programme of Comoros, the Guangzhou University of Chinese Medicine, and the Comoros Ministry of Health ( Figure 1 ). Informed consent was provided by individuals, parents, or guardians, as appropriate. Consent forms were kept for 3 years after completion of the MDA. A campaign to inform and engage Anjouan inhabitants was launched in concert with the Comoros Ministry of Health and National Malaria Control Programme. Information and discussions were promoted through announcements about the MDA programs on radio stations (300 times), on television stations (20 times), in newspapers (90 times), on posters (3500 items), in brochures (10 100 pieces), and on banners (340 items); provision of MDA explanations to women and students by international and local non-profit organizations (Women's Human Rights Organization, Women's Family, Women's Legal Aid Center, the Red Cross, middle schools, and university venues); and MDA discussions with village leaders and religious elders after presentations by the government officials of Comoros and the malaria control team of Guangzhou University of Chinese Medicine (155 events).
Malaria Control Network and MDA Administration
Malaria control teams consisting of 4100 village malaria volunteers, 236 village malaria workers, and 14 district malaria workers was organized and assigned the responsibility to visit every household, keep villagers informed of MDA activities, administer treatments, and monitor for MDA-associated adverse events. A "village-district-county-island" malaria surveillance-response system was concurrently established, with 7 diagnostic laboratories plus 7 district-and 97 county-level malaria control centers.
After a comprehensive census of Anjouan households, MDA of either AP alone or AP+PMQ LD was assigned in 3 monthly rounds from October-December 2012 (medicines supplied by Artepharm, People's Republic of China). The decision of which districts were to receive PMQ was based on logistics and population numbers, with attention to clear instructions to staff and organized data collection. Risk of possible adverse events from PMQ was a further consideration. After discussions with regional and national health authorities, the decision was made to include PMQ in MDA for a smaller population of 97 164 residents (~1/3 of the total) in 28 villages of the Pomoni and Domoni districts, while AP alone was offered to the 224 471 residents of 69 villages in the Mutsamudu, Ouani, Sima, Tsembehou, and Miremani districts. Medicine doses (Supplementary Table 1) were given under direct observation. Pregnant women within 3 months of conception, children <6 months old, and patients with liver or kidney diseases were excluded from MDA and received care as recommended by the Comoros Ministry of Health.
Microscopic Diagnosis of Parasitemias
Informed consent was obtained from adults or the legal guardians of children, and finger-prick blood samples were collected for peripheral thick and thin blood smears. After preparation and staining with 10% Giemsa solution, the smears were sent to the malaria laboratories in local district hospitals for examination by certified malaria microscopists. A negative smear was recorded if no parasite was observed in at least 200 fields with an oil immersion lens (100×). Of the negative smears, 10% were randomly selected and re-examined by a second microscopist to confirm the quality of the determinations. Any discrepancies were reviewed in conference and resolved, if necessary, by the readings of a third microscopist.
Monitoring and Treatment of Travelers
We monitored travelers at the airport (1) and wharfs (98) of the Island. Each traveler was asked to complete an information form and provided with an AP dose to take either immediately (recommended) or later if fever developed. Individual travelers were also asked to visit a malaria diagnostic laboratory to have a free microscopic check for Plasmodium infection.
Surveillance for MDA-associated Adverse Events
On days 1 and 4 after the start of each MDA round, subjects were interviewed for adverse events, including any appearance of dark urine, and these individuals were clinically evaluated if indicated. In addition to a standard symptom questionnaire, subjects were asked to answer open-ended questions such as "Do you feel different in any way since starting the drug treatment course?" Subjects experiencing adverse events were attended on site by a doctor or referred to a local district hospital for care.
PCR Amplification and Analysis of PfK13 Propeller Sequences
Blood samples before or after MDA were obtained from subsets of patients who presented with symptoms and P. falciparum parasitemia. Whole blood (1 ml) was collected in an EDTAcontaining vacutainer tube (Sangon Bio Inc., Shanghai, China) and stored at −20°C. DNA was isolated from 100 μl of each blood sample using the Takara DNA Blood Mini Kit (Takara, Japan). After polymerase chain reaction (PCR) amplification (Supplementary Table 2 ), nucleotide sequencing was performed with an ABI PRISM3730 DNA sequencer (Sangon Bio Inc., Shanghai, China).
Statistical Analyses
Data from April-September 2012 and from April-September 2013 (Supplementary Table 3) were analyzed by a quasi-Poisson model as described in Supplementary Appendix 1. of the whole district populations were achieved with AP and AP+PMQ LD , respectively, with improved participation in each round. The rounds of MDA excluded 2.3-2.6% of the population as women pregnant < 3 months, 3.1-3.6% as infants <6 months old, and 0.03-0.04% as patients with liver or kidney diseases (Supplementary Table 4) .
RESULTS
MDA Coverage
A total of 81 212 travelers were recorded at the airport and wharfs for the 27-month period of October 2012-December 2014. Of these travelers, 82.3% (66 837) took a therapeutic dose of AP immediately; 10.6% (8608) opted to carry the dose and treat themselves if they developed fever during their journey; and 7.1% either avoided an interview or declined to participate. Table 3) . District-by-district analyses were performed by quasi-Poisson modeling and compared to malaria rates on Grand Comore Island, where control programs of bednet distributions, diagnosis, and treatment were continued without MDA in a setting of higher Plasmodium indices and anthropogenic reservoirs of transmission [11, 12] . No malaria-associated deaths were reported on Anjouan Island in the 18 months after completion of the MDA programs, compared to 6 deaths in April-September 2012, prior to MDA (Supplementary Table 3 ). In contrast, mortality on Grande Comore Island remained virtually unchanged: 10 malaria-associated deaths were reported in April-September 2012, and 9 such deaths in April-September 2013. Quasi-Poisson cluster analysis of these deaths could not be performed as for the non-fatal malaria cases: the models do not converge because there were no deaths among the AP+PMQ LD and AP only groups in the post-treatment months.
Reduction of Parasitemia Rates in Children
Before MDA, parasitemia rates among children 0.5-16 years old ranged from 9.8% (52/531, Domoni) to 15.8% (69/436, Pomoni), and averaged 13.5% (383/2841) across the 7 districts (Supplementary Table 5 ). In the 2 districts treated with AP+PMQ LD , average parasitemia rates in children decreased to 1.2% (12/994), 0.7% (7/985), and 0.6% (6/991) at 6, 12, and 18 months post-MDA, respectively. Similarly, in the 5 districts treated with AP, average parasitemia rates in children decreased to 1.1% (22/1925 ) at 6 months post-MDA, 0.7% (13/1879) at 12 months post-MDA, and 0.5% (9/1792) at 18 months post-MDA. Among the samples examined 6 months post-MDA, gametocytes were detected by microscopy in 7 of the 994 (0.7%) children treated with AP+PMQ LD and in 9 of the 1925 (0.5%) children treated with AP (Fisher's exact test, 2-sided P = .434). 
MDA-associated Adverse Events
A total of 865 114 treatments of AP+PMQ LD or AP were monitored for MDA-associated adverse events (260 364 for AP+PMQ LD and 604 750 for AP). There were 504 mild adverse events recorded within 4 days of the MDA rounds (153 after AP+PMQ LD and 351 after AP), amounting to an overall incidence of 0.58/1000 persons (Supplementary Table 6 ). Headache was most common (0.12/1000 persons), followed by loss of appetite (0.11/1000 persons), dizziness (0.11/1000 persons), and nausea (0.09/1000 persons). No MDA-associated deaths or other serious adverse events were reported.
Prevalence of PfK13 Propeller Polymorphisms in P. falciparum Isolates Table 2 lists the PfK13 polymorphisms found in 248 successful PCR products from 271 P. falciparum-infected blood samples collected before or after MDA. None of these polymorphisms showed a statistically significant difference in prevalence between the 2 periods (Supplementary Appendix 1) .
DISCUSSION
In endemic settings, PMQ LD is effective against P. falciparum gametocytes and is recommended by the World Health Organization for transmission control [15] [16] [17] [18] . Recent studies found that posttreatment gametocytemias and gametocyte carriage times were reduced by addition of low PMQ doses to different ACTs (artemether-lumefantrine or dihydroartemisinin-piperaquine) [19, 20] ; however, a dry season study in Eastern Sudan found that the addition of PMQ to MDA of artesunate-sulfadoxine-pyrimethamine did not contribute to the reduction of gametocyte carriage and parasitemia rates [21] . Recent modeling has predicted limited advantages from the addition of PMQ LD to MDA in highly malarious regions [22] . In agreement with this modeling, our comparison on Anjouan Island of AP+PMQ LD vs. AP alone found effectiveness of >99%
for both programs, with no substantive contribution of PMQ LD on MDA outcomes. Together, the MDA programs of AP+PMQ LD and AP alone were associated with a reduction from 7362 total cases among 321 635 Anjouan residents in April-September 2012, before the start of MDA, to 47 total cases 1 year later, in April-September 2013 (99.4% decrease). Among the ~420 000 individuals on Grand Comore Island, where standard malaria control programs were maintained but no MDA programs were yet implemented, hospital malaria cases in these same periods decreased by only 27.8%, from 36 449 to 26 324 cases ( Table 2) . Success of MDA in the Anjouan setting involved training and programmatic operations similar to those for programs of Fast Elimination of Malaria by Source Eradication (FEMSE) in Cambodia [8, 23] and on Moheli Island [24] , as well as for earlier programs in China [25] [26] [27] . Operations included: (1) institution of an integrated malaria control network, including diagnostic laboratories, district-and county-level malaria control centers, and a "village-district-county-island" surveillance response system; (2) presentations of the MDA programs and discussions of malaria transmission by mass media in concert with international/ local non-profit organizations, religious elders, and local representatives, including village leaders; and (3) recruitment and activation of malaria control teams, including village-and district-level workers responsible for door-to-door visits and MDA distributions, with attention to local customs and sensitivities conducive to trust and participation. All MDA operations on Anjouan Island were instituted in harmony with ongoing programs of long-lasting insecticidal net distributions, indoor residual spraying, active case detection, and focal outbreak investigations.
Malaria parasite rates among randomly selected Anjouan children decreased from an average of 13.5% prior to MDA to 1.2%, 0.7% and 0.5% at 6, 12 and 18 months after MDA, respectively. These reductions in parasite rate (92-96%) were somewhat less than the 99.4% and 100% reductions achieved for morbidity and mortality. Likely explanations for the greater reductions of morbidity and mortality, as well as the trend to lower parasitemia rates 6, 12, and 18 months after MDA, include: (1) the success of continued follow-up case detections and outbreak management by the malaria control teams; (2) heightened malaria awareness and treatment-seeking, encouraged by the malaria educational programs; and (3) integration of malaria control activities on Anjouan Island within the overall Comoros National Health Development Plan [3, 28] . Residual parasite rates after MDA in this study were comparable to those found after 2 rounds of AP+PMQ LD on Moheli Island in 2007 (1.4% and 0.33% at 2 and 4 months after MDA, respectively, from an average rate of 23% before MDA) [24] . The MDA doses of AP+PMQ LD and AP in this study were well tolerated without serious untoward drug reactions or adverse events. Safety and a similar absence of severe adverse events after treatments of various artemisinin derivatives plus piperaquine, with or without PMQ LD , have been reported previously [8, 24, 29, 30] .
Treatment of P. falciparum malaria in the Comoros Archipelago has not yet encountered the drug resistance to ACTs that is now common in regions of Southeast Asia [31] [32] [33] . Whether MDA regimens may promote or reduce the emergence and spread of anti-malarial drug resistance remains an open question [34] [35] [36] . Polymorphisms C580Y, R539T, Y493H, and I543T of the PfK13 propeller sequence are considered to be markers of a P. falciparum ring-stage artemisinin survival phenotype that may be associated with parasite clearance rates [37] ; however, none of these polymorphisms were detected in the present study. Results instead identified 6 non-synonymous polymorphisms (D464H, S477Y, N490H, V520A, N554H, and A578S) already reported from other islands of the Comorian Archipelago [38, 39] . None of these polymorphisms showed significant differences in their frequencies before and after MDA.
Continued attention to robust control measures will be required to improve on these gains from MDA, and to eliminate the residual parasites that threaten renewed outbreaks of transmission. Inter-island migration acts as a continual source of malaria infections in the Comorian Archipelago, including the French Island of Mayotte where antimalarial programs have entered the elimination phase [40] . The steep decline of malaria and eventual entry of Anjouan into the elimination phase is thus an important contribution, integrated with other malaria control activities in the Comoros National Health Development Plan [3, 24, 28, 41] . In other malarious regions with similar epidemiological conditions, rapid control may likewise be achievable by appropriately-implemented MDA regimens of ACT without PMQ LD . Questions remain: for example, will PMQ LD show important benefit in programs where the number of rounds or drug combinations of MDA are different, or in instances where malaria endemicities and transmission conditions are distinct from those on Anjouan? Will PMQ LD prove useful against low-incidence outbreaks in post-MDA and low-transmission settings? The challenges now are to address these questions, build on the potential of MDA, and proceed to elimination.
